Patrys GmbH

Patrys was formed in December 2006 to consolidate leading natural human antibody technologies, deep product candidate pipelines and capabilities from the inventor of the technologies, which were previously located at the University of Wuerzburg in Germany , private German company OncoMab GmbH, and private American company Acceptys, Inc.

Patrys Limited (ASX: PAB) listed on the Australia Stock Exchange on 13 July 2007.

Patrys retained key personnel and capabilities from the University of Wuerzburg , OncoMab and Acceptys in an international corporate structure that it believes is well suited to participate in the global biotechnology sector.

Patrys functions are located in three regions:

• Australia : Headquarters are in Melbourne , Australia . The Australian team is responsible for corporate governance, administrative, financial and general management functions, and managing the lead product development program. The company's recombinant technology R&D team is based in Melbourne .

• Europe : The key personnel responsible for discovery of Patrys' lead products are employed by wholly-owned German subsidiary, Patrys GmbH to continue development of the product pipeline.

• United States : The Company has built a strong US-based regulatory and manufacturing team. This team will be employed by a wholly-owned US subsidiary, Patrys, Inc.

In addition, Patrys has taken a preferred equity interest in Acceptys, which will pursue infectious disease applications of the company's technologies.